Sign inJoin free

Watch / CEOs & MDs

US Defense Department show of support for this small cap

15 July 20244:09

US Defense Department show of support for this small cap

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Recce Pharmaceuticals (ASX: RCE) receives a $2 million grant from the US Department of Defense for burn wound infection treatment development

  • The company has also completes $8 million institutional placement for further medical R&D

  • CEO optimistic about developmental progress, especially the phase three diabetic foot infection study in Indonesia.

Recce Pharmaceuticals' CEO James Graham, details the receipt of a $2 million grant from the US Department of Defense. The grant is designed to assist the development of a new gel engineered to treat burn wound infections in military environments and help prevent complications such as sepsis. James explains that Recce Pharmaceuticals has been working closely with the US Department of Defense for 18 months, and this grant validates the substantial opportunity their compound offers against a broad spectrum of antimicrobial-resistant organisms or broad spectrum bacterial infections.

In addition to this grant, Recce Pharmaceuticals has completed a successful $8 million institutional placement. The raised funds will mainly be allocated to the company's IV programme, focusing on neuro sepsis. So far, the company's compound is showing promise in the efficacy against urinary tract infection or bacterial cells and against diabetic foot infections. The programme has also extended to a larger patient category, bacterial skin structure infection.

James expresses his pleasure with Recce Pharmaceuticals progress in developing new treatments. Recognising that patience is required in military collaborations, he is optimistic about the developments in the company's different programmes, especially the phase three diabetic foot infection study in Indonesia, and looking forward to the potential path to market through this registration status.

Full unedited transcript below:

0:00

Well, as you heard us report earlier, Recce Pharmaceuticals has received a $2 million grant from the US Department of Defense to develop its new gel, which is designed to treat burn wound infections and prevent complications like sepsis, especially in military settings. So let's get the details from recce CEO James Graham, who joins me now. Hi, James, welcome back to Aussies. I was a bit surprised by this. How did this US Department of Defense grant come about?

0:30

Well, it might be a surprise to some, but to us, it's been an opportunity we have worked on closely with the US Department of Defense for really some 18 months now. The US so US dollar $2 million grant is about 3 million AUD in true cash, non-discretionary cash and focused upon topical burn wound infections in the US military setting. And what could this lead to?

0:59

It leads to a lot of things. Firstly, it validates the significant opportunity that our compound represents when put against a broad spectrum, antimicrobial resistant organisms or broad spectrum bacterial infections. We know it's safe and well tolerated. We're not I.V. administered. We know it works well, of course, in a preliminary burn wound phase two study that we've conducted. And when we look to the complicated setting in the field of military personnel, we look to a broad range of factors, but a compound that works and keeps on working with repeated use and works faster than any other antibiotic known to date, is a compound that the US Department of Defense has said serves well, and they would like to have a go with that. So we're very well placed to support that with this 33 million Australian dollar grant. Okay. Well congratulations on that. Now you've also successfully completed an $8 million institutional placement. So what are the funds

1:58

being raised for James.

2:01

Yeah. So the we really break our categories down to our IV programs focused upon neuro sepsis. We recently showed that our compound, when IV administered, comes through to demonstrate an efficacious ability against urinary tract infection or urinary tract bacterial cells. We've also demonstrated our compounds to be efficacious against diabetic foot infections. And we've translated that program across to what's called an ab C program or, um, a bacterial skin structure infection. So a much bigger category, uh, of course, from a patient perspective, then it's the third category, military use and military use, as this provides, uh, is focused upon that grant, whereas the other $8 million is focused upon the, the two preliminary applications. So near-term catalysts are coming from that, which of course is what this funding represents.

3:01

Okay. We've been speaking, James, since the launch of OBS 2020, I think. Are you pleased with the progress that's being made? Are things happening fast enough for you?

3:14

Look, they are I think when we look to military settings, we must be patient. We recognise recognize there is a significant due diligence that the um, personnel of the US Department of Defense undertake when reviewing to provide a grant or to consider a compound for use on their military personnel. When we look to our other programs, of course, and we take a portfolio perspective of not just one compound for one indication, but compounds for a major infectious disease category of patients. And when we look to such a category, we see some move quickly, some move slowly. The one that is moving quickly, I would suggest, would be our registration or phase three diabetic foot infection study in Indonesia. I see where you've got a registration status, you have a near-term sales opportunity. And of course that represents a path to market.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy